CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

J. Knipper & Company

Rajeev Nair, CIO

Life Sciences: Macro View

Rajeev Nair

In Pharma, as R&D budgets come under heavy pressure, industry continues to be fraught with M&A aimed at product and patent acquisition. So integration continues to be a key concern to gain efficiencies and develop a single, unified compliance and regulatory layer; however, gone are the days where you could afford a multi-year rigid, monolithic ERP rollout; not just because of prohibitive costs, but also time for value recognition.


Healthcare market is going through rapid changes given new regulations – so pharma companies are extremely hungry for market intelligence - product efficacy, patient compliance, market penetration & reimbursement related - Analytics, not just the ability to integrate internal operational and sales data with market data, both structured & unstructured, but also be able to generate predictive behaviors becomes key. This means that the life sciences industry cannot afford to rely on single platforms or solution (providers) to meet the changing market needs. The need to seamlessly partner with various providers, both established and disruptive, who have USPs in niche areas becomes key.


Technology Implications: Need a New Model


The above macro factors point to a key technology theme – agility


• M&A - Agility to integrate up and down the value chain and with new acquired entities


• Analytics - Agility to partner with external data providers and integrate with internal operational data


• Changing Market needs - Agility to build flexible integration points that allow the enterprise to quickly partner with upcoming and disruptive service providers for niche needs


The traditional landscape that is riddled with monolithic applications like traditional ERP, CRM, BI systems don’t allow the flexibility and agility that today’s needs demand. Configurable services with flexible integration points become important as instantaneous integration becomes critical; in addition, for a service provider who provides end to end solutions like JKC, the ability to provide a platform where clients could pick and choose specific elements of the service portfolio to be integrated with their operations.


However, at the same time, traditional values don’t go away – predictability, compliance needs, efficiency etc. These needs almost seem like the antithesis of agility and flexibility.


More flexible and agile architectures that have faster integration platforms and configurable services become vital to survive and excel in this landscape – an example is micro-services architecture. In a micro-services architecture, software applications are developed as a suite of small, independently deployable modular services, in which each service serves a unique purpose and communicates through a clearly defined, light weight mechanism. Such an architecture has several advantages:


•Agility breeds scalability – a highly popular, in demand service can be deployed in multiple, more powerful servers to meet an increased need. This works really well with both in-house and IaaS and PaaS (cloud) landscapes where metered boosting of performance at a service level will be possible. Hard to achieve that through traditional IT deployment models


• Agility enables technology/platform agnosticism: Ability to choose specific technology for each service – this becomes vital while responding to specific providers in the market driving technology platform decisions


• Agility enables compliance – since each service serves a unique purpose and can be changed independent of each other, testing becomes easier due to higher predictability, and it drives compliance costs lower


• Agility breeds predictability and reduces risk: Contrary to large monolithic applications, since each service exists independent of each other, the potential of failure of one service doesn’t impact any others


• Agility enables quick integration, thus faster results: Loosely defined, light weight integration allows faster integration with the in-house organization’s and its providers’ and customers’ applications – this provides the agility an organization needs to have to respond to changing market needs.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/cioviewpoint/life-sciences-macro-view-nwid-54.html